奥他万古霉素通过破坏金黄色葡萄球菌和耐万古霉素肠球菌的细胞膜完整性来实现快速杀菌。
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
机构信息
The Medicines Company, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1.
出版信息
Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.
Abstract
Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. In this study, we demonstrate that oritavancin causes bacterial membrane depolarization and permeabilization leading to cell death of Gram-positive pathogens and that these effects are attributable to the 4'-chlorobiphenylmethyl group of the molecule.
摘要
奥他万古霉素是一种临床开发中的糖肽类抗生素，用于治疗急性细菌性皮肤和皮肤结构感染。在这项研究中，我们证明奥他万古霉素可导致革兰氏阳性病原体的细胞膜去极化和通透性增加，从而导致细胞死亡，而这些作用归因于该分子的 4'-氯联苯甲基基团。
相似文献
1
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.奥他万古霉素通过破坏金黄色葡萄球菌和耐万古霉素肠球菌的细胞膜完整性来实现快速杀菌。
Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.
2
Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.奥利万星对耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌的超微结构影响
Antimicrob Agents Chemother. 2009 Feb;53(2):800-4. doi: 10.1128/AAC.00603-08. Epub 2008 Nov 24.
3
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.2011-2014 年欧洲和北美的临床感染分离的葡萄球菌、链球菌和肠球菌对奥利万星及其他比较药物的体外活性研究。
Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.
4
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.利用体外万古霉素检测结果预测新型长效脂糖肽奥利万星的敏感性。
Antimicrob Agents Chemother. 2015 Apr;59(4):2405-9. doi: 10.1128/AAC.05098-14. Epub 2015 Feb 9.
5
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.奥利万星及对照药物对金黄色葡萄球菌、粪肠球菌和屎肠球菌的时间杀菌动力学
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
6
Oritavancin: mechanism of action.奥利万星：作用机制。
Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. doi: 10.1093/cid/cir920.
7
Impact of human serum albumin on oritavancin in vitro activity against enterococci.人血清白蛋白对奥利万星体外抗肠球菌活性的影响。
Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.
8
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.生长阶段和pH值对新型糖肽类药物奥利万星（LY333328）体外抗金黄色葡萄球菌和粪肠球菌活性的影响。
J Antimicrob Chemother. 2002 Jul;50(1):19-24. doi: 10.1093/jac/dkf058.
9
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.奥利万星在体外可杀死处于稳定期和形成生物膜的金黄色葡萄球菌细胞。
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
10
Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.奥利万星：一种新型糖肽类抗生素，对包括多重耐药菌在内的革兰阳性病原体具有活性。
Int J Antimicrob Agents. 2010 Nov;36(5):401-7. doi: 10.1016/j.ijantimicag.2010.06.048. Epub 2010 Aug 21.
引用本文的文献
1
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?达巴万星和奥利万星用于革兰氏阳性菌感染的药理学比较综述：同类还是异类？
Infect Dis Ther. 2025 Sep 3. doi: 10.1007/s40121-025-01215-1.
2
Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.糖肽类抗生素：耐药性、临床药代动力学及药效学研究进展
Indian J Microbiol. 2025 Mar;65(1):32-50. doi: 10.1007/s12088-024-01273-y. Epub 2024 Apr 27.
3
Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?奥利万星导管封管溶液对葡萄球菌和肠球菌生物膜有活性吗？
Heliyon. 2025 Jan 10;11(2):e41885. doi: 10.1016/j.heliyon.2025.e41885. eCollection 2025 Jan 30.
4
In silico molecular targets, docking, dynamics simulation and physiologically based pharmacokinetics modeling of oritavancin.奥他万古霉素的计算机分子靶标、对接、动力学模拟和基于生理的药代动力学建模。
BMC Pharmacol Toxicol. 2024 Oct 22;25(1):79. doi: 10.1186/s40360-024-00804-z.
5
The role of long-acting antibiotics in the clinical practice: a narrative review.长效抗生素在临床实践中的作用：一篇叙述性综述。
Infez Med. 2023 Dec 1;31(4):449-465. doi: 10.53854/liim-3104-4. eCollection 2023.
6
The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.多剂量奥利万星的临床疗效：一项系统评价
Antibiotics (Basel). 2023 Sep 29;12(10):1498. doi: 10.3390/antibiotics12101498.
7
Staph wars: the antibiotic pipeline strikes back.葡萄球菌之战：抗生素管道奋起反击。
Microbiology (Reading). 2023 Sep;169(9). doi: 10.1099/mic.0.001387.
8
Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.靶向细菌细胞壁的抗生素和含碳水化合物药物：概述
Pharmaceuticals (Basel). 2022 Jul 29;15(8):942. doi: 10.3390/ph15080942.
9
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.近期获批抗生素对耐甲氧西林金黄色葡萄球菌（MRSA）菌株的抗菌活性：系统评价和荟萃分析。
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
10
Recent Developments in Methicillin-Resistant (MRSA) Treatment: A Review.耐甲氧西林金黄色葡萄球菌（MRSA）治疗的最新进展：综述
Antibiotics (Basel). 2022 Apr 29;11(5):606. doi: 10.3390/antibiotics11050606.
本文引用的文献
1
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.近期革兰阳性临床分离株的体外比较活性研究
Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.
2
Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.奥利万星对耐万古霉素、中介或异质性耐药金黄色葡萄球菌菌株的体外活性比较
J Antimicrob Chemother. 2009 Oct;64(4):868-70. doi: 10.1093/jac/dkp286. Epub 2009 Aug 4.
3
Vancomycin and oritavancin have different modes of action in Enterococcus faecium.万古霉素和奥利万星对粪肠球菌具有不同的作用方式。
J Mol Biol. 2009 Oct 9;392(5):1178-91. doi: 10.1016/j.jmb.2009.06.064. Epub 2009 Jul 1.
4
Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus.奥利万星可与分离的金黄色葡萄球菌原生质体膜结合，但不能与完整的原生质体结合。
J Mol Biol. 2009 Aug 14;391(2):414-25. doi: 10.1016/j.jmb.2009.06.033. Epub 2009 Jun 16.
5
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.特拉万星通过与细胞壁前体脂II的靶向相互作用破坏细菌膜的功能完整性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
6
Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization.奥利万星（一种源自万古霉素的新型脂糖肽）与磷脂双层的相互作用：对膜通透性和纳米级脂质膜组织的影响。
Biochim Biophys Acta. 2009 Sep;1788(9):1832-40. doi: 10.1016/j.bbamem.2009.05.003. Epub 2009 May 18.
7
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.奥利万星及对照药物对金黄色葡萄球菌、粪肠球菌和屎肠球菌的时间杀菌动力学
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
8
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.成人患者万古霉素的治疗监测：美国卫生系统药师协会、美国传染病学会和传染病药师协会的共识综述
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434.
9
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.奥利万星在体外可杀死处于稳定期和形成生物膜的金黄色葡萄球菌细胞。
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
10
Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.奥利万星具有双重作用模式，可抑制金黄色葡萄球菌细胞壁的生物合成。
J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17.
Zotero 插件